Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Tag: moderate-to-severe Crohn’s disease
#VisualAbstract: Risankizumab was Non-Inferior to Ustekinumab for the Clinical Remission of Moderate-to-Severe Crohn’s Disease
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Upadacitinib therapy effective at inducing remission in Crohn’s disease
1. In this randomized controlled trial, upadacitinib resulted in higher remission rates for patients with Crohn’s disease compared to a ...
